VolitionRx recently had data published in the peer-reviewed journal Clinical Epigenetics, which confirmed the utility of the NuQ platform for detecting pancreatic cancer. Also, combining NuQ assays with the CA 19-9 biomarker, it was able to achieve 92% sensitivity and 90% specificity. Additionally, the company announced interim data from a 4,800-subject trial in colorectal cancer (CRC) and received its first CE mark in Europe for an assay for the detection of CRC.